Daily PubMed evidence board
Avelumab Plus Methotrexate for Gestational Trophoblastic Tumors: The TROPHAMET Phase 1/2 Nonrandomized Clinical Trial.
This multicenter phase 1/2 trial tested giving avelumab (an anti-PD-L1 antibody) together with methotrexate as the first treatment for women with low-risk…
Signal score51Research triage score
CertaintyLowVerify in full text
PMID42275082Source identifier
Research triage, not medical advice
Do not use this summary, score, or benefit-cost estimate to diagnose, treat, prescribe, or change care without reviewing the full study and consulting qualified professionals.
Verify before acting
Check full-text methods, eligibility, outcomes, risk of bias, harms, conflicts, funding, replication, and applicability.
Plain-English signal
This multicenter phase 1/2 trial tested giving avelumab (an anti-PD-L1 antibody) together with methotrexate as the first treatment for women with low-risk gestational trophoblastic tumors (GTT). Among 27 patients treated (26 assessable), almost all (96.2%) achieved blood markers of disease remission (hCG normalization); no relapses were seen after ~41 months median follow-up. The combination had an acceptable safety profile with one dose-limiting toxicity (grade 3 sepsis) and no grade 4+ events; most immune- or treatment-related events resolved, except one ongoing grade 2 thyroid dysfunction. Among patients wanting pregnancy, 13 of 14 became pregnant. These findings suggest the combination is promising but come from a nonrandomized early-phase study and require confirmation in randomized trials before changing standard care.
Why it matters
- Addresses first-line treatment for low-risk gestational trophoblastic tumors (GTT; FIGO score ≤6), a condition where standard single-agent chemotherapy cures ≈70% of patients.
- Tests combining an immune checkpoint inhibitor (avelumab) with methotrexate as initial therapy, which could change first-line care if comparative benefit and safety are confirmed.
- Reports high hCG normalization (efficacy) and preserved fertility in this multicenter cohort - outcomes directly relevant to reproductive-aged patients and oncology treatment planning.
Primary outcomes
- Phase 1 primary endpoint: dose-limiting toxic effects (DLTs).
- Phase 2 primary endpoint: rate of serum hCG normalization permitting treatment discontinuation.
Effect summary
In 27 treated patients (26 assessable) with low-risk GTT (FIGO score ≤6), avelumab 800 mg IV plus methotrexate 1 mg/kg IM produced hCG normalization in 96.2% (90% CI, 85.9%-97.9%); one DLT occurred and no grade 4+ events were reported. Median follow-up was 41 months with no relapses observed; among those desiring pregnancy, 13/14 achieved pregnancy.
Benefit-cost lens
| Quick take | Early-phase nonrandomized evidence of high biochemical response and manageable safety for avelumab+methotrexate in low-risk GTT; useful for monitoring and planning comparative studies, not for practice change. |
|---|---|
| BCR anchor | 1 |
| Time horizon | 3 |
| Discount rate | 0.03 |
| Assumptions | Assessment uses abstract-reported outcomes only. No head-to-head randomized comparator data in this report; assume treated cohort reflects typical low-risk GTT referral population but verify full-text eligibility and selection. |
Benefit-cost fields are assumptions-based unless explicitly source-derived. Treat them as prompts for deeper economic review.
Risk of bias
| Tool | rapid-abstract-screen |
|---|---|
| Verdict | Higher uncertainty |
| Notes | Nonrandomized, single-arm phase 1/2 study with small sample size; abstract-only information limits assessment of selection bias, outcome ascertainment, handling of missing data, and detailed adverse event reporting. Trial registration is provided in abstract (NCT04396223) but full protocol and statistical analysis details need review. |
Harms, equity, conflicts & implementation
| Implementation | Before implementation: randomized comparative evidence, full safety profile, treatment protocol details, infusion capacity, cost analysis (drug and monitoring), reproductive counseling pathways, and payer coverage considerations. |
|---|---|
| Equity impact | Unclear from abstract. Potential equity concerns if avelumab infusion access, cost, or referral patterns limit availability to centers or populations; fertility outcomes may differentially affect subgroups and should be reported by sociodemographic factors. |
| Harms | Abstract reports one DLT (grade 3 sepsis on central venous catheter), immune- or treatment-related adverse events grade ≥2 in 22% (mostly resolved except 1 case of grade 2 dysthyroidism), and no grade 4+ events. Full AE spectrum, late toxicities, and pregnancy-related safety require full-text and larger studies. |
| Registration | NCT04396223 |
| Replication | Unknown from this report; no replication data provided in abstract. |
Source links — verify original
Use PubMed and full-text links to confirm methods, population, outcomes, harms, conflicts, and applicability.